Alerta

INHIBITOR OF Aβ175 OLIGOMERS/AGGREGATES AND USE THEREOF

Resumen de: WO2026076634A1

Provided are Aβ375 related oligomers/aggregates in human brains and anti-Aβ3175 related oligomers/aggregates antibodies thereof. In addition, the using of anti-Aβ3175 related oligomers/aggregates antibodies for the treatment of Alzheimer's disease (AD) is also provided.

Vaccines and Antibodies for the Treatment and Prevention of Neurodegenerative Disorders and Inflammation Related Health Conditions

Resumen de: US20260102478A1

The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and/or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and/or limbic predominant age-related TDP-43 encephalopathy (LATE).

ヒト脳海馬領域における空間トランスクリプトミクスに基づくアルツハイマー病の診断及び鑑別診断のための方法、システム、組成物及び試薬キット

Resumen de: CN117761317A

According to the method, system, composition and kit for diagnosis and differential diagnosis of the Alzheimer's disease based on human brain hippocampus space transcriptomics, differential diagnosis of the Alzheimer's disease is achieved through one or more of CCK, Neurogranin and PMP2 carried by plasma extracellular vesicles (EVs). The core detection technology of the application is a nanoflow detection technology, focuses on clinical and scientific research problems of early diagnosis and differential diagnosis of AD cognitive impairment, and performs high-sensitivity and high-throughput detection on nervous system source EVs in peripheral blood through an international leading space transcriptome and single cell sequencing and a brand-new nanoflow detection technology; the method has the advantages of high speed and low cost, utilizes human brain resources, innovatively discovers the EVs markers of the brain region and cell specific sources of the central nervous system, realizes rapid and efficient early diagnosis and differential diagnosis of AD cognitive impairment, and provides a new technical means and method for clinical application of clinical AD cognitive impairment and large-scale screening related accurate diagnosis work.

ASSESSING AND TREATING PARANEOPLASTIC NEUROLOGIC SYNDROME

Resumen de: WO2024258729A2

This document provides methods and materials for assessing and/or treating mammals having a paraneoplastic neurologic syndrome (PNS). For example, methods and materials for using a Sloan Kettering virus family transcriptional corepressor 2 (SKOR2) polypeptide and/or one or more fragments of a SKOR2 polypeptide to detect the presence or absence of autoantibodies present in immune-mediated PNS are provided.

p-Tau205特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Resumen de: CN121851162A

0001 本申请公开了一种p‑Tau205特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域，本申请提供了靶向p‑Tau205的抗体、检测p‑Tau205的化学发光试剂盒。本申请的抗体亲和力高、灵敏度高和生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域。本申请公开的试剂盒可以用于与p‑Tau205相关的疾病，例如阿尔茨海默症的辅助诊断。

ＣＤＫＬ５欠乏症のための治療

Resumen de: WO2024165736A1

Disclosed herein are methods and agents for the treatment and/or prevention of cyclin dependent kinase like 5 (CDKL5) deficiency disorder. In particular, disclosed herein are compounds or compositions for increasing cyclin dependent kinase like 2 (CDKL2) in a subject, such as in the brain of a subject, and the use of those compounds and compositions in methods of treating CDKL5 deficiency disorder

流体試料内に極微量に存在する分析対象物質の粒子を検出するための方法

Resumen de: KR102543112B1

The present invention relates to a method for detecting particles of a substance to be analyzed present in a minimum amount in a fluid sample. The method comprises the steps of: flowing a fluid sample containing a substance to be analyzed, on a substrate having an array of microchambers to the surface of which a first capture material specifically binding to the substance to be analyzed is fixed; allowing the substance to be analyzed to bind to the first capture material in each microchamber of the array of microchambers; flowing a second capture material specifically binding to the substance to be analyzed and binding to a signal generating material, on the substrate to react the substance to be analyzed with the second capture material; flowing the signal generating material on the substrate to bind to the second capture material; flowing, on the substrate, a substrate solution reacting with the signal generating material to generate a fluorescent signal; flowing a hydrophobic solvent on the substrate, and removing the substrate solution outside the microchamber when the signal generating material and the substrate solution react with each other inside the microchamber; and counting the number of microchambers in which the fluorescent signal has occurred, and detecting the same. Therefore, the concentration of molecules or particles present in a minimum amount in a fluid sample can be more easily calculated.

一种基于GALNT10检测辅助评估阿尔兹海默症早期风险的方法

Resumen de: CN121852530A

0001 本发明公开了一种基于GALNT10检测辅助评估阿尔兹海默症早期风险的方法。所述方法为体外非诊断性分析方法，包括：对受试者的生物样本中GALNT10的生物标志物水平进行检测，并基于检测结果获得用于评估该受试者AD早期风险的信息。所述生物标志物包括GALNT10基因型、GALNT10 mRNA表达水平或GALNT10蛋白浓度。通过对血浆中GALNT10蛋白浓度的定量检测来实现风险评估时，具体可采用包含针对GALNT10蛋白不同表位的捕获抗体和检测抗体的免疫检测试剂盒进行。本发明通过检测受试者生物样本中GALNT10的蛋白浓度、基因型或mRNA水平，获得用于风险判定的客观信息，实现了对AD上游病理机制的早期、无创监测，为疾病早期预警提供了新策略。

一种胶质瘤手术边界识别标志物及其应用

Resumen de: CN121852543A

本发明公开了一种胶质瘤手术边界识别标志物及其应用。本发明首次确认了SERPINA3可以作为识别胶质瘤侵袭边界的标志物，可以有效辅助胶质瘤术前或术中手术规划及肿瘤切除，提高手术切除精度，为胶质瘤临床诊断和治疗提供了有效分子工具，具有显著的应用前景。

一种基于EFEMP1检测辅助评估阿尔兹海默症早期风险的方法

Resumen de: CN121856564A

0001 本发明公开了一种基于EFEMP1检测辅助评估阿尔兹海默症早期风险的方法。所述方法为体外非诊断性分析方法，包括：对受试者的生物样本中EFEMP1的生物标志物水平进行检测，并基于检测结果获得用于评估该受试者AD早期风险的信息。所述生物标志物包括EFEMP1基因型、EFEMP1 mRNA表达水平或EFEMP1蛋白浓度。通过对血浆中EFEMP1蛋白浓度的定量检测来实现风险评估时，具体可采用包含针对EFEMP1蛋白不同表位的捕获抗体和检测抗体的免疫检测试剂盒进行。本发明通过检测受试者生物样本中EFEMP1的蛋白浓度、基因型或mRNA水平，获得用于风险判定的客观信息，实现了对AD上游病理机制的早期、无创监测，为疾病早期预警提供了新策略。

一种阿尔茨海默症筛查标志物、抗体、试剂盒及方法

Resumen de: CN121856567A

0001 本发明属于生物技术及医学检测技术领域，具体公开了一种阿尔茨海默症筛查标志物、抗体、试剂盒及方法，该筛查标志物为血浆外泌体中的SRC蛋白；所述抗体能特异性识别所述血浆外泌体中SRC蛋白；一种阿尔茨海默症筛查的方法包括：获取待测个体的血浆样本；从血浆样本中提取外泌体；使用抗体检测所述外泌体中SRC蛋白的表达水平；将表达水平和参考值进行比较，若表达水平高于参考值，则提示所述个体患有阿尔茨海默症的风险。本发明能无创对阿尔茨海默症进行早期筛查，且操作便捷、成本低、具有高敏感性和特异性。

ニドゲンをベースとする足場タンパク質および治療用ナノ複合体

Resumen de: EP3842452A1

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

LRP1-β链短肽作为靶标在治疗主动脉夹层中的应用

Resumen de: CN121818897A

本发明公开了编码LRP1‑β链短肽的基因作为靶标在筛选/制备治疗主动脉夹层的药物中的应用，诱导LRP1‑β链短肽过表达的试剂在制备治疗主动脉夹层的药物中的应用，以及LRP1‑β链短肽作为生物标志物在制备主动脉夹层诊断试剂中的应用。通过实验首次证明了LRP1‑β链短肽可通过下调OPN的表达抑制血管平滑肌细胞表型转化和巨噬细胞炎症浸润，减轻炎症反应，可缓解或抑制主动脉夹层发生发展，为主动脉夹层的治疗提供了新的方向和思路，有望应用在治疗主动脉夹层的新药研发中。

特发性常压脑积水生物标志物、诊断试剂盒及应用

Resumen de: CN121831168A

本发明公开了特发性常压脑积水生物标志物、诊断试剂盒及应用，属于生物医药技术领域，尤其涉及一种特发性常压脑积水生物标志物，所述生物标志物为蛋白质生物标志物，包括NBL1、TREM2、COL3A1、DPP7、PLA1A、SELENBP1、FGB、CCK、WFIKKN2、KNG1、HBA2、GFRA3、CSF1。特发性常压脑积水生物标志物在制备特发性常压脑积水诊断试剂盒中的应用。本发明通过DIA技术筛选差异蛋白，PRM技术验证蛋白表达，筛选得到了特发性常压脑积水生物标志物，用于iNPH的早期筛查、风险评估和预后判断，实现了对iNPH的早期、准确、客观诊断，缩短临床诊断周期，提升诊疗效率。

腸透過性を判定するための方法

Resumen de: WO2024189211A1

The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.

阿尔茨海默相关神经丝蛋白检测试纸条、其制备方法及应用

Resumen de: CN121831160A

本发明公开了一种阿尔茨海默相关神经丝蛋白检测试纸条、其制备方法及应用，包括：底板，以及沿第一端向第二端的方向依次设置在所述底板上的双层样品垫、结合垫、硝酸纤维素膜和吸水垫；其中，沿第一端向第二端的方向为待测样品在该试纸条上的流动方向；本发明的试纸条中的双层样品垫由分别采用不同方式处理的两层聚酯纤维膜搭接形成，结合垫上喷涂有不同粒径的乳胶微球混合物与抗体偶联得到的标记物，且偶联方法采用低温超声偶联法，通过以上对试纸条制备方法的改进，使得本发明制备得到的试纸条具有抗基质干扰能力强、检测准确性高、灵敏度高、线性范围广、检测速度快、稳定性强、检测结果可肉眼可视化判读，适用于AD大规模早筛等优势。

一种抗重组sCD40L的鼠源单克隆抗体及其制备方法与用途

Resumen de: CN121824765A

0001 本发明公开了一种抗重组sCD40L的鼠源单克隆抗体及其制备方法与用途，属生物医药领域。本发明以重组sCD40L免疫BALB/c小鼠，经杂交瘤技术获4株稳定分泌单抗的细胞株HYD‑5048‑01至04，单抗亚型为IgG1/κ和IgG2b/κ，Kd值达nM级，重、轻链可变区序列（SEQ ID NO.1‑16）为全新序列。经ELISA、Western blot及免疫组化验证，所有单抗均可特异性结合sCD40L。其中，5048‑02的F(ab')2片段（DT1）可减轻血栓及器官纤维化症状；5048‑03靶向血栓性疾病；5048‑02/04对神经退行性疾病、自身免疫病及器官移植排斥有防治潜力。本发明提供的单抗兼具高特异性和强亲和力，为相关药物研发提供全新工具。

インフラマソーム関連疾患又は病態を処置するための組成物及び方法

Resumen de: JP2026062733A

【課題】炎症性疾患の診断を支援可能なバイオマーカーとその使用方法。【解決手段】多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害のマーカーとして、対象からのサンプル中のインフラマソームの成分を検出するための組成物及び方法。多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害を有する対象について、予後を判定し、処置を指示し、且つ処置に対する反応をモニタリングするためにかかるインフラマソームマーカーを使用する方法も記載される。【選択図】図３２

用于确定细胞中蛋白质及其衍生物的方法和工具

Resumen de: WO2025056667A1

Method for the determination of at least one structural and/or physico-chemical property of at least one protein or peptide or of properties thereof, said at least one protein or peptide contained in a complex mixture of further proteins and/or other biomolecules in at least one cell, comprising the following steps: 1. delivery of a protease into said cell and limited proteolysis of the complex mixture, followed by cell extraction and/or cell lysis leading to a fragment sample; 2. denaturation of the fragment sample to a denaturated fragment sample; 3. optional complete fragmentation of the denaturated fragment sample in a digestion step to a completely fragmented sample; 4. analytical analysis of the fragmented sample or the completely fragmented sample for the determination of said at least one protein or peptide or of properties thereof.

ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用

Resumen de: JP2026510789A

本発明は、ＰＡＭの立体構造エピトープに対する少なくとも１つの結合剤を含むアッセイを使用して、体液又は組織試料中のＰＡＭ及び／又はそのアイソフォーム及び／又はその断片のレベルを決定するための方法、並びに診断目的のためのその使用を対象とする。【選択図】なし

認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置

Resumen de: US11826321B2

0001 Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用

Resumen de: CN121831157A

0001 本发明涉及血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用。包括以下步骤：以NEV/OEV作为辅助鉴别PD和MSA的诊断指标，其中，NEV为RT‑QuIC实验中得到NEV反应终点荧光信号最大值，OEV为RT‑QuIC实验中得到OEV反应终点荧光信号最大值。与现有技术相比，本发明首次使用外周血结合α‑syn扩增技术来鉴别鉴别PD和MSA，实现PD与MSA的高效鉴别，填补了外周血中外泌体结合α‑syn扩增技术鉴别两种疾病的空白。

一种基于血浆神经元来源外泌体在抑郁症诊断中的应用

Resumen de: CN121831145A

本发明公开了一种基于血浆神经元来源外泌体在抑郁症诊断中的应用，利用血浆提取神经元来源外泌体检测血清中的 NDEVs 并检测 USP11水平，发现抑郁症患者的 NDEVs 中 USP11 显著高于健康对照，因此血清中的 NDEVs中 USP11水平可以反映颅内神经细胞状态的生物状态，该检测在抑郁症的诊断中能够显著提高检测特异性和敏感度，具有很高的临床应用价值。

基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统

Resumen de: CN121831127A

本申请公开了基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统。基于梯度核酸编码和毛细管电泳的多组学联检方法包括以下步骤：设计长度和序列均不相同的多个寡核苷酸对；制备标记探针对；反应杂交形成寡核苷酸对；生成对应于待测物的DNA模板；产生带有标记物的、长度各异的DNA扩增产物；制备毛细管电泳谱图；鉴定出对应的待测物种类；和/或，对相应的待测物进行定量分析。该方法在临床诊断、生物标志物发现、蛋白质、基因和代谢组学等生命科学研究中具有广泛的应用前景。

改良された血液診断

Nº publicación: JP2026511083A 10/04/2026

Solicitante:

フジレビオユーロープナームローゼフェンノートシャップ

Resumen de: WO2024200207A1

A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.